🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOther Peptides & Research CompoundsDihexa nootropic peptide — what worked for you?

Dihexa nootropic peptide — what worked for you?

AmyNC_wife Tue, Sep 2, 2025 at 6:47 AM 16 replies 1,516 viewsPage 1 of 4
This thread is more than 9 months old. Information may be outdated. Consider searching for more recent discussions.
AmyNC_wife
Member
634
2,890
Jun 2024
North Carolina
Sep 2, 2025 at 6:47 AM#1

Writing this once so I can stop repeating it across threads. It is about the pharmacology, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

The condition it depends on

The adaptation point cuts both ways: tachyphylaxis to gastric emptying is why tolerability improves, and it is also why people who were relying on physical fullness feel the effect fade while the appetite effect is still working.

The practical version

Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.

What I am not sure about

The question I want answered is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. I have searched first, so if this is covered somewhere point me at it and I will read it.

— AmyNC_wife · corrections welcome and will be edited into this post with credit
10 5JessicaM_2024, TomFromTexas, mike.trainer_LA and 7 others
Reply Quote Save Share Report
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Sep 2, 2025 at 6:55 AM#2
AmyNC_wife said:
The pharmacokinetics explain nearly every practical question asked here.

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36). Three key modifications enable its pharmacokinetic profile:

  1. Aib8 substitution: DPP-4 resistance (prevents enzymatic degradation)
  2. Arg34 substitution: improved chemical stability
  3. C18 fatty diacid at Lys26: albumin binding → long half-life

These three modifications transform a peptide with a 2-minute half-life (native GLP-1) into one with a 168-hour half-life (semaglutide). A masterclass in peptide engineering.

Last edited: Sep 2, 2025 at 11:55 AM
9 4TinaHashiRN, robert_kc, dan_philly and 6 others
Reply Quote Save Share Report
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Sep 2, 2025 at 7:03 AM#3
AmyNC_wife said:
The pharmacokinetics explain nearly every practical question asked here.

Pushing back on AmyNC_wife here. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Last edited: Sep 2, 2025 at 9:03 AM
8 3cory_ATX, lori_vegas, Dr.PulmRoch and 5 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Sep 2, 2025 at 7:11 AM#4
Dr.LipidDallas said:
The mechanism is more central than most summaries suggest.

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].

Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.

Early-stage data — interpret with caution. But the trajectory is extraordinary.

References:
[1] Novo Nordisk investor presentation, September 2023.
Last edited: Sep 2, 2025 at 1:11 PM
7 2mike.trainer_LA, sarah_nash92, FitDadDave and 4 others
Reply Quote Save Share Report
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Sep 2, 2025 at 7:55 AM#5
PharmD_Rodriguez said:
Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36).

Same experience, arrived at from the opposite direction. I had assumed I was the exception until I read this.

6 1bbq_ray_KC, oliver_london, tane_welly and 3 others
Reply Quote Save Share Report

Similar Threads

BPC-157 oral vs injectable — bioavailability review and evidence15 replies
TB-500 for tissue repair — mechanism and clinical evidence4 replies
Selank and Semax — anxiolytic peptides overview2 replies
CJC-1295/Ipamorelin combination — GH secretagogue discussion23 replies
BPC-157 + GLP-1 stacking for gut healing — N=1 experience17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register